2008 NSTI Nanotechnology Conference and Trade Show - Nanotech 2008 - 11th Annual
Technical Conferences
Merck Corporate Needs
NanoInk Symposium
Nano Electronics & Photonics
Nano Fabrication
MEMS & NEMS
Sensors & Systems
Micro & Nano Fluidics
MSM - Modeling Microsystems
WCM - Compact Modeling
Nanostructured Materials & Devices
Soft Nanotechnologies & Applications
Nanoparticles in Soft Materials - Colloidal Systems
Polymer Nanotechnology
Carbon Nano Structures & Devices
Nano Particles & Applications
Composites
Nanostructured Surfaces and Interfaces
Nanoscale Characterization
Energy Technologies & Applications
Nanotech in Health, Environment & Society
ICCN - Nanoscale Modeling
Nanoreliability
Bio Nano Materials & Tissues
Bio Sensors & Diagnostics
Biomarkers & Nanoparticles
Cancer Diagnostics, Imaging & Treatment
Drug Delivery & Therapeutics
Nano Medicine
Nanotech to Neurology
Phage Nanobiotechnology
Clean Technology 2008
Industrial Impact Workshop
Confirmed Speakers
Program Committee
Reviewers

Partnering Events:

TechConnect Summit
Clean Technology 2008

Imaging Phage Probes

Kimberly A. Kelly

Kimberly A. Kelly

Assistant Professor
Massachusetts General Hospital / Harvard Medical School

Dr. Kelly received her Bachelor’s of Arts degree in Chemistry in 1992 from Hamilton College in upstate New York. She subsequently studied biochemistry with Dr. David A. Jones, PhD at the Huntsman Cancer Institute/University of Utah and received a Ph.D. degree in 2002. Dr. Kelly’s graduate work focused on the development of targeted agents for the early detection of colon cancer. Dr. Kelly accepted a T32 postdoctoral fellowship position with Dr. Nathaniel Alpert, PhD. Under the guidance of Dr. Ralph Weissleder, MD, PhD, Dr. Kelly’s postdoctoral research focused on the development of novel targeted molecular probes utilizing optical, and magnetic resonance imaging modalities. Following two years of postdoctoral research, she became an Instructor in Radiology and an Assistant in Biochemistry at the Center for Molecular Imaging Research, MGH/Harvard Medical School. Recently, Dr. Kelly was promoted to an Assistant Professor.

Dr. Kelly’s laboratory is interested in applying powerful combinatorial approaches to the development of targeted and amplifiable imaging agents. We currently use several different strategies including phage display, small molecule display on nanoparticles, peptoids, receptor mimetics and SELEX. Over the last few years we have developed and optimized many of the screening protocols that are unique to imaging agents. Through the use of these approaches, we have now generated imaging agents that have been able to detect colon cancer, pancreatic, and prostate cancers as well as specific targets in atherosclerosis. A second research interest is target identification of novel imaging agents identified through the above screens. For example we had previously identified the peptide sequence RPMC as one, which, specifically targets colon cancer and have subsequently shown it to be a target for αvβ1. Similarly, we have identified peptide sequences subsequently shown to target VCAM-1 and the endothelial protein SPARC, which has been shown to play an important role in tumorigenesis.

Speaking in the special symposium on Phage Nanobiotechnology.


View Confimed Speakers

← Back to Conferences & Symposia